ETCM
TXG icon

Evolutionary Tree Capital Management’s 10x Genomics TXG Stock Holding History

Evolutionary Tree Capital Management’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-33,169
Closed -$1.5M – 37
2022
Q2 		$1.5M Sell
33,169
-20,959
-39% -$1.09M 1.63% 28
2022
Q1 		$4.12M Buy
+54,128
New +$4.74M 2.86% 15

Other funds holding TXG

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $11.2B AUM 0.58% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Evolutionary Tree Capital Management's TXG Position: Q3 2022 in Review

Evolutionary Tree Capital Management sold out of 10x Genomics (TXG) in Q3 2022, closing a stake of 33,169 shares — an estimated $1.5M sold.

Evolutionary Tree Capital Management first reported a position in TXG in Q1 2022 and held it in 2 quarters. The position peaked at $4.12M in Q1 2022. 233 funds tracked by Wall St. Rank hold TXG as of Q3 2022.

  • Evolutionary Tree Capital Management reported no remaining 10x Genomics position as of Q3 2022 after selling out during the quarter.
  • Evolutionary Tree Capital Management sold 33,169 10x Genomics shares in Q3 2022, an estimated $1.5M.
  • Evolutionary Tree Capital Management first reported a position in 10x Genomics in Q1 2022 and held it in 2 quarters.
  • Evolutionary Tree Capital Management's 10x Genomics position peaked at $4.12M in Q1 2022.
  • 233 funds tracked by Wall St. Rank held 10x Genomics as of Q3 2022.

Based on Evolutionary Tree Capital Management's 13F filing for Q3 2022, filed 10 Nov 2022.